Bli medlem
Bli medlem

Du är här

2016-03-15

Enzymatica AB: The board of directors in Enzymatica has resolved on a rights issue of SEK 60 million

This press release may not be published or distributed, directly or
indirectly, in or into the United States, Australia, Japan, Canada, Hong
Kong, New Zeeland, Singapore or South Africa or any other jurisdiction where
such action is subject to legal restrictions.

Press Release
Lund on 15 March 2016

The board of directors in Enzymatica AB (publ) (the "Company") has on 14 March
2016 resolved on a rights issue with pre-emptive right for the shareholders,
subject to approval by the extraordinary shareholders' meeting. The rights
issue, which was announced in connection with the acquisition of Zymetech on
28 January 2016, is secured up to 100 per cent by subscription undertakings
and guarantee undertakings representing approximately SEK 60 million. The
subscription price in the rights issue is SEK 2.18 per share. Notice to the
extraordinary shareholders' meeting is published in a separate press release.

Background and reasons

In 2015, the Company increased sales by 46 percent to SEK 27.9 million,
compared to approximately SEK 19 million during 2014, primarily as a result
of continued strong sales on the Swedish market of ColdZyme Mouth Spray
against the common cold. Moreover, ColdZyme is sold on five more markets;
Denmark, Norway, Finland, the UK and since the beginning of 2016 in Spain. In
2015, the Company put in a lot of work on building the foundation for the
continued international expansion, including establishing a quality
management system and other measures for compliance with international
directives for medical devices. In the end of January the Company signed an
agreement to acquire the Icelandic company Zymetech through a share issue.
The transaction was approved on an extraordinary general meeting on 15
February 2016. Zymetech is an important complement to the Company's business.
The acquisition gives the Company access to patent protection for ColdZyme
throughout Europe and a dozen or so additional countries. It gives the
Company opportunity to offer distributors exclusive distribution rights,
which facilitates the international expansion. The acquisition also gives the
Company control of the enzyme production and access to Zymetech's research
expertise in enzyme technology and research portfolio.

It is the Company's belief that the existing working capital is not sufficient
for the current needs for the next twelve months. To finance the Company's
operations going forward and to carry out the international expansion board
of directors in the Company resolved, subject to shareholder approval, on an
issue of shares with pre-emptive right for existing shareholders of
approximately SEK 60 million. The main reason for the rights issue is to
create financial sustainability for the Company in order to pursue commercial
opportunities more aggressively and thus promote a considerable long-term
sales growth for the cold product ColdZyme.

The proceeds from the forthcoming rights issue will be used to finance the
Company's geographic expansion, cover product development costs, including
trial and product documentation, and continued operating activities. The
rights issue together with existing cash and cash flows from operating
activities is estimated to cover the Company's financing needs for more than
twelve months.

The board of directors have also proposed, in the notice to the extra general
meeting, authorisation to carry out a directed share issue of no more than
17.5 million new shares. The reason for the authorisation of a directed share
issue is, if the market allows for it, to take advantage of future
opportunities to bring in long-term strong owners and to further finance the
Company's growth strategy.

Terms and details of the rights issue

The board of directors in the Company has on 14 March 2016 resolved on a
rights issue with pre-emptive right for the shareholders, subject to approval
by the extraordinary shareholders' meeting, of a maximum of 27,520,428
shares, each with a quotient value of SEK 0.04. Existing shareholders of the
Company's will receive subscription rights to subscribe for new shares in
proportion to the shares held on the record date of participation on 19 April
2016. Each share held on the record date of participation entitles to one (1)
subscription right. Five (5) subscription rights confers right to subscribe
for three (3) new shares. The subscription price in the rights issue is SEK
2.18 per share. At full subscription, the total rights issue proceeds will be
approximately SEK 60 million before transaction costs.

If not all shares are subscribed for by exercise of subscription rights in
accordance with the shareholders preferential rights mentioned above, the
board of directors shall resolve on allotment up to the maximum amount of the
share issue. In such case, priority will be given firstly to those who have
also subscribed for shares by exercise of subscription rights, on the
occasion of oversubscription, pro rata in relation to their subscription for
shares by exercise of subscription rights and, to the extent not possible, by
drawing of lots. Secondly, allotment of shares subscribed for without
subscription rights shall be made to others who have subscribed for shares
without subscription rights, if full allotment is not possible, pro rata in
relation to their subscription for shares and, to the extent not possible, by
drawing of lots. Thirdly, allotment of shares shall be made to those who have
provided guarantees for the subscription of shares, pro rata in relation to
the guarantee provided.

Subscription and guarantee undertakings

The rights issue is fully secured by existing shareholders along with external
guarantors. Existing shareholders have undertaken to subscribe for 10 million
SEK, corresponding to approximately 17 percent of the rights issue. The
remaining 50 million SEK, corresponding to approximately 83 percent, of the
rights issue has been secured by external guarantee undertakings.

Timetable for the rights issue

-----------------------------------------------------------------------------------
| 14 April Extraordinary shareholders' meeting |
| 14 April Last day of trading inclusive subscription rights |
| 15 April First day of trading exclusive subscription rights |
| 19 April Record date for participation in the rights issue |
| 20 April Estimated date for publication of the prospectus |
| 21 April - 2 May Trading in subscription rights |
| 21 April - 6 May Subscription period |
| 10 May Estimated day for announcement of outcome of the rights issue |
-----------------------------------------------------------------------------------
Advisers

ABG Sundal Collier has served as the financial adviser and Setterwalls as the
legal adviser to the Company in connection with the rights issue.

For more information, contact:
Fredrik Lindberg, CEO Enzymatica AB

Tel: +46 (0)708-86 53 70 | Email:fredrik.lindberg@enzymatica.com

About Enzymatica AB

Enzymatica is a life science company whose business concept is to offer
effective help against some of our most common diseases where viruses or
bacteria play a decisive role. Over a short period the company has developed
a unique oral spray for colds, ColdZyme®, and launched it on six markets.
Since launch the product has become one of the leading articles for colds in
Swedish pharmacies. Development includes medical devices in upper respiratory
infections and oral health, and veterinary products. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North. For more
information, please visitwww.enzymatica.com.

Enzymatica's certified adviser is Erik Penser Bankaktiebolag.

Important information
The information in this press release does not contain or constitute an offer
to acquire, subscribe or otherwise trade in shares, subscription rights or
other securities in Enzymatica AB (publ). Any invitation to the persons
concerned to subscribe for shares in Enzymatica AB (publ) will only be made
through the prospectus that Enzymatica AB (publ) estimates to publish on or
about 20 April 2016.

This press release may not be published or distributed, directly or indirectly
in or into the United States, Australia, Japan, Canada, Hong Kong, New
Zeeland, Singapore or South Africa or any other jurisdiction where such
action is wholly or partially subject to legal restrictions or where such
action would require additional prospectuses, registrations or other actions
in addition to what follows from Swedish law. Nor may the information in this
press release be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or would require such requirements. Failure to
comply with this instruction may result in a violation of applicable
securities laws.

No subscription rights, interim shares or new shares have been registered, and
will not be registered, under the United States Securities Act of 1933
("Securities Act") or securities legislation in any other state or other
jurisdiction in the United States and may not be offered, subscribed, sold or
transferred, directly or indirectly within the United States, other than
pursuant to an exemption from the registration requirements of the Securities
Act and in accordance with securities laws in relevant state or other
jurisdiction in the United States.

This press release may contain forward-looking statements which reflect
Enzymatica AB (publ):s current view on future events and financial and
operational development. Words such as "intend", "expect", "anticipate",
"may", "believe", "plan", "estimate" and other expressions which imply
indications or predictions of future development or trends, and which are not
based on historical facts, are intended to identify forward-looking
statements. Forward-looking statements inherently involve both known and
unknown risks and uncertainties because they depend on future events and
circumstances. Forward-looking statements do not guarantee future results or
development and the real outcome could differ materially from the
forward-looking statements.

Press Release (PDF)
http://hugin.info/160850/R/1994303/734374.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1994303

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.